For over a century, the treatment of breast cancer has been defined by the knife. From Halsted's radical mastectomy to the modern era of breast-conserving surgery, the fundamental assumption has remained the same: the tumor must be cut out. However, a growing body of evidence now suggests that for a select group of women with early-stage, low-risk breast cancer, another option may provide similar outcomes. Cryoablation, which is a minimally invasive technique that destroys tumors by freezing them, is emerging as a safe, effective, and patient-centered alternative to surgery.
The strongest signal comes from two landmark prospective trials. The FROST trial, a Phase 2 multicenter study, recently reported six-year outcomes for 83 women aged 50 and older with stage I, hormone receptor-positive, HER2-negative invasive ductal carcinoma. At a median follow-up of 6.1 years, post-ablation biopsy showed no residual cancer in virtually all patients, and the five-year ipsilateral breast tumor recurrence rate was just 3.64%, with an invasive recurrence-free survival of 97.59%. These performance metrics are similar to those of surgical treatment. No serious adverse events were reported.
The ICE3 trial is another fundamental study evaluating breast cancer cryoablation. Among 194 women aged 60 and older with unifocal tumors 1.5 cm or smaller, the five-year ipsilateral breast tumor recurrence rate was 4.3% at a mean follow-up of 54 months, with breast cancer survival of 96.7%. No serious device-related complications occurred.
These recurrence rates were similar to those historically reported after breast-conserving surgery with radiation, which ranged from around 3% to 5% at five years in similar low-risk populations. Of course, the comparison is not perfect, as no randomized trial has yet placed cryoablation head-to-head against lumpectomy, but the consistency of results across multiple prospective studies, with follow-up now extending beyond five years, is promising.
It’s important to note that cryoablation is not a replacement for surgery in all breast cancers. The data are clear that success depends on patient selection. The ideal candidate is a woman aged 60 or older with a unifocal, ultrasound-visible invasive ductal carcinoma measuring 1.5 cm or smaller, histologic grade 1 or 2, hormone receptor-positive, HER2-negative, and clinically node-negative. Tumor size also plays a role, with studies demonstrating 100% complete ablation for tumors 15mm or smaller, compared with roughly 85% for larger lesions. The presence of an extensive ductal carcinoma in situ component also reduces efficacy.
These restrictions reflect the biology of the tumors most amenable to thermal destruction and the patient populations in whom the risk-benefit calculus most clearly favors a less invasive approach. For an 80-year-old woman with a small, indolent, hormone-sensitive cancer, the morbidity of general anesthesia, surgical recovery, and potential wound complications may represent a greater threat to quality of life than the cancer itself. Cryoablation, performed under local anesthesia in an outpatient setting, changes that equation.
Beyond clinical outcomes, the financial case for cryoablation is compelling. A recent cost-effectiveness analysis of cryoablation versus breast-conserving surgery found that cryoablation achieved comparable health outcomes at significantly lower cost, saving at least $17,682 per patient. A direct comparison study of the two approaches reported mean costs of $2,221.70 for cryoablation versus $16,896.50 for surgical resection, a difference that was highly statistically significant. In an era of escalating healthcare expenditures and growing attention to value-based care, these numbers matter. In many patients, cryoablation can produce equivalent oncologic outcomes at a fraction of the cost while improving patient-reported quality of life, including physical, sexual, and cosmetic well-being.
Despite this encouraging data, cryoablation remains conspicuously absent from major societal guidelines as a standard-of-care option. Critics point to the lack of randomized controlled trials, the relatively small sample sizes, and the single-arm designs of existing studies. A Lancet Oncology consensus review identified outstanding issues including optimal patient selection, long-term follow-up, and standardization of technique as barriers to routine adoption. However, a major milestone for cryoablation was its recent FDA approval for the treatment of breast cancer in October 2025.
Cryoablation continues to evolve. Researchers are exploring multi-probe approaches to extend cryoablation to larger tumors, and early-phase trials are investigating the combination of cryoablation with checkpoint inhibitors, leveraging the immunogenic cell death produced by freezing to generate systemic antitumor immunity. If these strategies prove successful, the eligible patient population could expand considerably.
The path forward requires several concrete steps. First, professional societies will need to formally acknowledge cryoablation as a reasonable option for carefully selected patients and develop consensus guidelines for patient selection, technique, and follow-up. Second, insurers must establish clear coverage policies to prevent patients and physicians from having to navigate repeated prior authorization disputes on a case-by-case basis. Third, the research community should prioritize a well-designed, multicenter randomized trial comparing cryoablation to breast-conserving surgery.
Finally, we must listen to patients. Surgery has pioneered many of the most significant advances in breast cancer care, evolving from highly invasive procedures to more precise, breast-conserving techniques that improve survival while preserving patients’ quality of life. Today, for patients who fall under the criteria, cryoablation may be an alternative pathway toward less pain, faster recovery, better cosmetic outcomes, and higher satisfaction. In a disease where survival rates for early-stage, low-risk cancers already exceed 95% regardless of local treatment modality, quality of life is not a secondary endpoint; rather, it is the endpoint that matters most.
For the right patient with the right tumor, cryoablation offers a glimpse of a future in which cancer treatment is not only effective but also proportionate, humane, and aligned with what patients actually want. It is time to stop treating this technology as experimental and start treating it as what the evidence increasingly shows it to be: a legitimate, evidence-based alternative whose time has come.
